EB Clinical Research Consortium (EBCRC) Grants

EBCRC Grants

Runs research teams and institutions for EBCRC Grants in biotechnology and medical technology.

The EB Clinical Research Consortium (EBCRC) Grants are administered by the EB Research Partnership (EBRP), a 501(c)(3) nonprofit headquartered at 244 Madison Avenue, New York, founded in 2010. EBRP describes itself as the largest global organization dedicated to funding research to treat and cure Epidermolysis Bullosa, a rare and severe genetic skin blistering disorder. The EBCRC program specifically targets clinical-stage research conducted through the EB Clinical Research Consortium network, distinguishing it from EBRP's companion Research Project Grants, which support earlier-stage commercially viable therapeutic work.

The next EBCRC application cycle opens in Q3 2026. Both nonprofit institutions and universities are eligible applicants; for-profit entities and individuals are not. Indirect costs are capped at 5 percent across all EBRP grant programs, and applicants must provide Humane Care documentation and Human Subjects approval where relevant. EBRP operates under a venture philanthropy model in which it retains a royalty or financial interest in funded research, reinvesting returns into further EB work. Award amounts for the EBCRC program are not published publicly; applicants must access the SmartSimple portal at ebresearch.us-1.smartsimple.com to obtain full program details and the request for proposals.

Projects that focus purely on pre-clinical work without a clinical component should apply to the Research Project Grants stream instead. Competitive applications under both programs are expected to demonstrate a commercially feasible path to EB therapies within a defined timeframe and include explicit commercialization plans. Submitters should contact EBRP directly at 646-844-0902 to confirm award amounts, scoring criteria, and specific EBCRC eligibility conditions before the Q3 2026 window opens.